Feature | March 12, 2014

Partnership Investigates Remote Robotic PCI at Rural Hospitals

Corindus CorPath Robotic Navigation Telemedicine Telecardiology Cath Lab

March 12, 2014 — For patients living in rural areas, life-saving procedures such as an angioplasty may only be available at a facility more than 200 miles away. To bridge this distance, Corindus Vascular Robotics is partnering with Sanford Health and The Leona M. and Harry B. Helmsley Charitable Trust to launch a feasibility study for a remote robotic systems cath lab telecardiology program. 

Following the feasibility study, the remote robotics program is intended to potentially empower an interventional cardiologist at a major center to robotically control the movement of interventional devices at a remote facility. This could offer patients located in rural areas the high-quality heart care and treatment currently available only at heart centers in major metropolitan areas. The first phase of the program aims to understand what is required to make remote robotics successful. The development of the program will proceed based on those findings.

With funding from The Leona M. and Harry B. Helmsley Charitable Trust, Corindus and Sanford Health will pursue pioneering remote capabilities for robotic-assisted percutaneous coronary intervention (PCI).

CorPath is an U. S. Food and Drug Administration (FDA)-cleared technology. It enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. Physicians sit in a lead-lined interventional cockpit protected from radiation exposure. CorPath allows the cardiologist to advance stents and guidewires millimeter-by-millimeter using joysticks and touchscreen controls. The remote robotics program is intended to extend the capability of CorPath to not just perform angioplasty in the same cath lab, but in labs hundreds of miles away. 

For more information: www.corindus.com

Related Content

Stereotaxis, Niobe remote magnetic navigation system, Philips Allura Xper FD10 cardiovascular X-ray, interface, integration
News | Robotic Systems| January 20, 2017
Stereotaxis Inc. announced the release of an interface between its remote magnetic navigation system for...
Biotronik, BioMonitor 2 implantable cardiac monitor, BioInsight clinical study, first patients enrolled
News | Implantable Cardiac Monitor (ICM)| January 20, 2017
Biotronik has enrolled the first patients in the BioInsight clinical study evaluating the safety and feasibility of...
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillators (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
stress, brain activity, cardiovascular risk, PET-CT, MGH, ISSMS, The Lancet study
News | Cardiac Diagnostics| January 18, 2017
A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (ISSMS) investigators...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillators (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
University of Utah, Frank Sachse, heart failure, LVAD implantation, left ventricular assist device, biomarker, t-system

Two patients may seem equally sick based upon clinical measures, but differences in their heart physiology could predict who has the potential to recover from heart failure. A study carried out by scientists at the University of Utah finds that patients whose hearts have flattened t-tubules have a decreased chance of showing signs of recovery after implanting a mechanical heart pump. Ordinarily, t-tubules in the heart are long, thin, and rounded. Image courtesy of Frank Sachse.

News | Cardiac Diagnostics| January 17, 2017
Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
Overlay Init